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Cell surface molecules that can act as virus receptors may exert an important selective pressure on RNA viral
quasispecies. Large population passages of foot-and-mouth disease virus (FMDV) in cell culture select for
mutant viruses that render dispensable a highly conserved Arg-Gly-Asp (RGD) motif responsible for integrin
receptor recognition. Here, we provide evidence that viability of recombinant FMDVs including a Asp-1433Gly
change at the RGD motif was conditioned by a number of capsid substitutions selected upon FMDV evolution
in cell culture. Multiply passaged FMDVs acquired the ability to infect human K-562 cells, which do not
express integrin avb3. In contrast to previously described cell culture-adapted FMDVs, the RGD-independent
infection did not require binding to the surface glycosaminoglycan heparan sulfate (HS). Viruses which do not
bind HS and lack the RGD integrin-binding motif replicate efficiently in BHK-21 cells. Interestingly, FMDV
mutants selected from the quasispecies for the inability to bind heparin regained sensitivity to inhibition by a
synthetic peptide that represents the G-H loop of VP1. Thus, a single amino acid replacement leading to loss
of HS recognition can shift preferential receptor usage of FMDV from HS to integrin. These results indicate
at least three different mechanisms for cell recognition by FMDV and suggest a potential for this virus to use
multiple, alternative receptors for entry even into the same cell type.
RNA viruses mutate at rates of 1023 to 1025 misincorpora-
tions per nucleotide copied; as a consequence, they evolve as
complex mutant distributions termed viral quasispecies (17, 19,
34, 35, 51, 52, 54). Evolution of RNA viral quasispecies does
not occur by the steady accumulation of mutations as replica-
tion proceeds but rather proceeds as the outcome of popula-
tion disequilibrium in response to population size variations
and environmental modifications. This is reflected in frequent
fitness variations of RNA viruses as they replicate in cell cul-
ture or in vivo (3, 12, 18, 27, 29, 33, 42, 64; reviewed in
reference 16). Perturbation of equilibrium may lead to the
rapid dominance of subsets of variants which were previously
present at low frequency in the mutant spectrum. Expression at
the cell surface of particular molecules which can act as recep-
tors or coreceptors for the virus may have a major influence on
the mutant distributions in viral quasispecies.
Foot-and-mouth disease virus (FMDV) has been used in our
laboratory as a model system to study viral quasispecies evo-
lution, including the molecular basis of fitness variations (21,
22) and changes in host cell tropism (3, 20). FMDV is an
important animal pathogen that belongs to the aphthovirus
genus of the Picornaviridae family (5, 55) and infects cattle and
other cloven-hooved animals (artiodactyls) (2, 9). Integrin
avb3 was the first molecule identified as a primary receptor for
FMDV (4, 6, 24, 38). Recent evidence suggests that integrin
avb3 is the functional receptor for FMDV infections of cattle
(50). The integrin receptor recognition site includes a highly
conserved Arg-Gly-Asp (RGD) triplet located on the highly
mobile, exposed G-H loop of capsid protein VP1 (1, 30, 39,
41). Interestingly, this loop is also a major antigenic site for the
virus (7, 53, 60; reviewed in reference 45). Studies of site-
directed mutagenesis of infectious cDNA copies of the FMDV
genome (40, 44, 49), inhibition of infectivity by synthetic pep-
tides (48), and binding of antibodies to substituted peptides
(63) have defined those amino acid residues which are involved
in cell receptor recognition and antibody binding. In FMDV of
serotype C (clone C-S8c1, derived from natural isolate C-Sta
Pau Sp/70 [59]), the RGD motif is directly involved in both
integrin recognition (30, 48) and binding of several neutraliz-
ing antibodies (31, 56, 61–63). In spite of being subjected to
strong selective pressure by antibodies, the RGD triplet was
invariant among natural FMDV isolates, in populations of
FMDV C-S8c1 subjected to intense selection by neutralizing
antibodies (8), and among 81 monoclonal antibody (MAb)
escape mutants of FMDV C-S8c1 (43, 46, 47). In contrast, a
viral population resulting from 100 serial cytologic passages of
FMDV C-S8c1, termed FMDV C-S8c1p100, generated an al-
tered repertoire of MAb-resistant (MAR) mutants that in-
cluded variants with substitutions at the RGD motif (43, 56).
Cell surface heparan sulfate (HS) can substitute for FMDV
integrin receptor, and FMDV variants with improved affinity
for heparin are frequently selected after propagation in cell
culture (3, 37, 50, 57). Very recently, the crystallographic struc-
ture of the FMDV capsid of serotype O1 complexed with
heparin has been determined (25). Interaction with heparin
often involves the acquisition of positively charged residues on
the viral capsid (3, 25, 57).
In this study, we used a collection of natural and engineered
FMDVs to provide evidence that some FMDV variants lacking
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the RGD necessitate additional capsid substitutions for infec-
tivity and that they must use some alternative entry pathway
which requires an interaction with neither integrin avb3 nor
HS. The results suggest the potential use of at least three
alternative receptors for entry of FMDV into the same cell
type.
MATERIALS AND METHODS
Cells and viruses. The origins of baby hamster kidney 21 (BHK-21) and
Chinese hamster ovary (CHO) cell lines used in this study have been previously
described (13, 15, 59). Human K-562 erythroleukemia cells were kindly provided
by M. Fresno. BHK-21 cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco) supplemented with nonessential amino acids (Gibco) and 5%
fetal calf serum (Gibco). K-562 cells were grown as suspension cultures in the
same medium but in the presence of 10% fetal calf serum.
FMDV C-S8c1 is a plaque-purified derivative of the European serotype C
natural isolate C1 Santa Pau-Spain 70 (59). FMDV C-S8c1p100c10 is a plaque-
purified clone derived from a population obtained after 100 serial cytolytic
passages of C-S8c1 in BHK-21 cells (C-S8c1p100) described in reference 43.
FMDV C-S8c1p100RGG is a C-S8c1p100-derived MAR mutant with an Asp-
1433Gly change at the integrin recognition Arg-Gly-Asp motif (43). FMDV
C-S8c1p100c10 and C-S8c1p100 RGG differ only in one amino acid (VP1 posi-
tion 143) in their capsids. The FMDV C-S8c1 population at passage 213, termed
C-S8c1p213, was used to select MARLS, a MAR mutant which includes the
alteration Leu-1443Ser in VP1 (13, 46). Procedures for infections of cell mono-
layers and plaque assays with FMDV have been previously described (15, 59).
Virus growth curves. FMDV single-step growth curves were determined by
infecting BHK-21 cell monolayers (106 cells) at a multiplicity of infection of 5
PFU/cell. Virus was allowed to adsorb at 37°C for 1 h; then monolayers were
washed once with 0.1 M phosphate buffer (pH 6.0), washed twice with DMEM,
and further incubated in 2 ml of DMEM–2% fetal calf serum. At different times
after infection, samples were taken for titration of infectivity on BHK-21 cell
monolayers as previously described (59). For K-562 cells growing in suspension,
virus adsorption was performed in 250 ml of culture medium (2 3 106 cells) at a
multiplicity of infection of 2 PFU/cell, with gentle rocking at 37°C for 1 h. Cells
were washed with 0.1 M phosphate buffer (pH 6.0) before further incubation in
2 ml of culture medium. Samples were centrifuged for 5 min at 1,500 3 g before
titration of infectivity.
cDNA synthesis, PCR amplification, and nucleotide sequencing. Viral RNA
extraction, cDNA synthesis, and reverse transcription-PCR (RT-PCR) amplifi-
cation were performed as previously described (21). Consensus nucleotide se-
quences were determined on PCR-amplified DNA either in an automated se-
quencer (ABI373) or by using a Thermo Sequenase cycle sequencing kit
(Amersham). The oligonucleotides used for RT-PCR and nucleotide sequencing
have been previously described (3).
Heparin-Sepharose binding assay and selection of FMDV variants with de-
creased affinity for heparin. Heparin-Sepharose binding assays and selection of
FMDV variants with decreased affinity for heparin were performed as previously
described (3).
Construction of full-length cDNA of FMDV O1K encoding type C capsid
proteins, in vitro transcription, and cell transfection. The numbering of FMDV
genomic residues is as described in reference 21. The adenosine residue of the
first functional AUG initiation codon is at nucleotide 1039; the capsid-coding
region spans nucleotides 1642 to 3834. Amino acid residues have been numbered
independently for each protein. The procedure used for construction of full-
length chimeric cDNAs of FMDV O1K encoding type C capsid proteins was
previously described (3). The region transferred to the O1K genetic background
spans Ser-33 of VP4 to Lys-62 of protein 2B and corresponds to FMDV genomic
positions 1739 and 4066 (NcoI-HindIII fragment) (Fig. 1). The BssHII-AvrII
fragment encoding the VP1 G-H loop of FMDV C-S8c1p100RGG (genomic
positions 3395 to 3757) was used to substitute an Arg-Gly-Gly (RGG, VP1
positions 141 to 143) sequence for the RGD integrin-binding domain in the
FMDV cDNAs (Fig. 1).
In vitro transcription was performed as previously described (3). The RNA
concentration was estimated by agarose gel electrophoresis and ethidium bro-
mide staining. RNA transcripts (0.1 to 1 mg) were introduced into BHK-21 cells
by the Lipofectin method or by electroporation (37). RNA from chimeric viruses
resulting from one round of replication after transfection was retrotranscribed,
and the regions encoding the capsid proteins and neighboring genomic regions
were sequenced. In all chimeric constructs, the expected nucleotide sequences
corresponding to serotype O FMDV were identified in the regions around those
encoding the capsid proteins.
Synthetic peptides. Peptide A15 (YTASARGDLAHLTTT), representing
amino acid residues 136 to 150 of the G-H loop of VP1 of C-S8c1, and its variant
peptide A15-RGG (YTASARGGLAHLTTT), in which an RGG was substituted
for the RGD sequence, were synthesized by solid-phase procedures as described
previously (11, 48). The peptides were at least 90% pure as determined by
high-performance liquid chromatography. Peptides were dissolved in phosphate-
buffered saline containing 1 mM CaCl2 and 0.5 mM MgCl2 at neutral pH, and
their concentration was determined by amino acid analysis (48). Assays of inhi-
bition of infectivity by synthetic peptides were carried out essentially as described
previously (30, 48).
RESULTS
FMDV replication independent of the RGD in VP1 is con-
ditioned by capsid alterations. To test the possible require-
ment of the RGD triplet in cell recognition by FMDV variants
of serotype C that differ in the degree of adaptation to BHK-21
cells, a number of chimeric viruses were constructed by cloning
the capsid-coding region of FMDV C-S8c1, and of several cell
culture-adapted derivatives, into a full-length cDNA of FMDV
strain O1K (65). Constructs included viruses with the capsid of
C-S8c1 (construct pO1K/C-S8c1), C-S8c1p100 (pO1K/p100),
and C-S8c1p213 (pO1K/p213). We constructed a second set of
chimeras that were identical to the former set except that they
encoded a VP1 G-H loop with RGG instead of RGD; they
were named pO1K/C-S8c1RGG, pO1K/p100RGG, and pO1K/
p213RGG, respectively (Fig. 1). Production of progeny virus was
determined upon transfection of BHK-21 cells with RNA tran-
scripts from each construct. Transfection with RNA transcripts
derived from cDNAs pO1K/p100, pO1K/p213, and their cor-
responding RGG variants resulted in cytopathologic changes
at about 24 h posttransfection that were indistinguishable for
transcripts expressing RGD or RGG in the G-H loop of VP1.
In contrast, cytopathologic changes were observed at about
48 h after transfection with transcripts derived from pO1K/C-
S8c1, and no cytopathic effect was observed upon transfection
with pO1K/C-S8c1 RGG. Infectivity for BHK-21 cells was con-
firmed for viral progeny derived from each transfection except
in the case of pO1K/C-S8c1 RGG, as expected from the lack of
cytopathology. All recombinant progeny maintained their chi-
meric nature after a second round of replication in BHK-21
cells, as evidenced by RT-PCR amplification of progeny RNA
and nucleotide sequencing. Progeny viruses were all neutral-
ized by serotype C-specific MAbs directed to antigenic site D
(39). The requirement for infectivity of an RGD triplet in an
FMDV capsid with the sequence context of FMDV C-S8c1 was
confirmed by a second series of experiments involving electro-
poration of BHK-21 cells with RNA transcribed from plasmid
pO1K/C-S8c1 RGG. When 106 BHK-21 cells were electropo-
rated with 1 mg of RNA, progeny virus was obtained (with a
delay of about 24 h with respect to parallel transfections with
FIG. 1. Schematic representation of the capsid-coding region of chimeric
FMDVs. Genomic regions of FMDV of serotype C (white boxes) are inserted in
the full-length cDNA of type O1K FMDV (3, 65). Origins of the viruses used for
construction of chimeric DNA and procedures employed for the preparation of
plasmids are detailed in Materials and Methods. Restriction sites and numbering
refer to the C-S8c1 genome (21). Positions at which amino acid residues differ
among the compared chimeric genomes are indicated at the bottom. The amino
acid sequence of protein VP4 is conserved among the FMDVs of serotypes O
and C analyzed here. Boldface letters correspond to amino acid residues which
differ from the parental C-S8c1.
1642 BARANOWSKI ET AL. J. VIROL.
RNA from pO1K/C-S8c1); it included mutation G-36353A
(amino acid change Gly-1433Asp in VP1), which implied a
true reversion to restore the RGD triplet. Identical reversion
was obtained upon electroporation of a pO1K/C-S8c1RGG
variant which included mutation G-30673A (amino acid re-
placement Glu-1733Lys in VP3). This marker mutation was
maintained in the RGD-containing revertant progeny, ruling
out possible contamination artifacts in the rescuing of infec-
tious virus. These results suggest that Asp-1433Gly is lethal in
the sequence context of the capsid of C-S8c1 but not in the
context of the capsid of C-S8c1p100 or C-S8c1p213.
The replication capacity of FMDV recombinants O1K/p100
and O1K/p213 was indistinguishable from that of the corre-
sponding mutants lacking the RGD motif (Fig. 2). Variants
with the capsid of multiply passaged FMDV reached titers
about 10-fold higher than that of FMDV O1K/C-S8c1. The
presence of RGG sequence characterizing recombinant FMDV
variants O1K/p100RGG and O1K/p213RGG was confirmed by
sequencing of the viral genomes collected at 24 h postinfection.
These results suggest that the presence of RGG instead of
RGD in C-S8c1p100 or C-S8c1p213 does not affect signifi-
cantly the infectivity of these viruses for BHK-21 cells.
Replication of recombinant FMDV variants in K-562 cells.
Human K-562 erythroleukemia cells express undetectable lev-
els of integrin avb3 (14) and are resistant to FMDV infection
unless cells are transfected with cDNAs encoding this integrin
(50). K-562 cells failed to sustain the replication of FMDV
O1K/C-S8c1 (viral titers of ,103 PFU/ml at 20 to 40 h postin-
fection). In contrast, FMDV O1K/C-S8c1p100 and O1K/C-
S8c1p213, either the version with RGD or the version with
RGG, replicated in K-562 cells, with viral titers in the range of
5 3 104 to 1 3 106 PFU/ml at 20 to 40 h postinfection (Fig. 3).
This result suggests that multiply passaged FMDV C-S8c1p100
and C-S8c1p213 replicate without the need of integrin avb3.
Binding to HS is not required for cell recognition by type C
FMDV variants that lack the RGD motif. Recent evidence
suggests that adaptation of FMDV to cell culture conditions
results in the selection of variant viruses able to utilize the
glycosaminoglycan HS as an alternative receptor molecule (3,
37, 50, 57). To determine the implication of HS glycosamino-
glycan in cell recognition by FMDV mutants that lack the
RGD motif, variant viruses with decreased affinity for heparin
were selected from FMDV populations C-S8c1p100c10 and
C-S8c1p100RGG. After five rounds of selection for negative
binding to heparin-Sepharose beads (3), five FMDV clones
unable to bind heparin were isolated from each subpopulation,
and their capsid-coding regions were sequenced. Loss of
heparin binding in C-S8c1p100c10 was associated with a single
amino acid replacement which was either Lys-1733Glu in VP3
(two clones, including c1) or Arg-1973His at the C-terminal
region of VP1 (three clones). Loss of heparin binding in
C-S8c1p100RGG was associated with the Lys-1733Glu
change in VP3 in each of the five clones analyzed. The two amino
acid substitutions involved in loss of heparin binding were
mediated by true reversions of two mutations (A-30673G in
the VP3-coding region and G-37973A in the VP1-coding re-
gion) that had been acquired by FMDV C-S8c1 in the course
of 100 serial passages in BHK-21 cells (Fig. 1). FMDV
C-S8c1p100RGG/hs-c1 infected wild-type and mutant pgsA-
745 and pgsD-677 CHO cells, with viral titers reaching 104
PFU/ml in all cases. Viral yields were 103-fold lower than those
produced by the parental virus able to bind heparin, but the
difference was independent of the expression of HS in the
CHO cells. Upon infection of BHK-21 cells, the viral yield by
clones which were defective in heparin binding was only 2- to
15-fold lower than the yield of their corresponding parental
FIG. 2. Replication of recombinant FMDV variants in BHK-21 cells. Monolayers of BHK-21 cells were infected with chimeric viruses harboring the capsid of
C-S8c1 (A), C-S8c1p100 and its RGG derivative (B), or C-S8c1p213 and its RGG derivative (C) at a multiplicity of infection of 5 PFU per cell. Procedures for the
infection in liquid culture and titration of infectivity are described in Materials and Methods. Each value represents the mean of triplicate assays.
FIG. 3. Replication of recombinant FMDV variants in K-562 cells. Cells
were infected with the indicated chimeric viruses at a multiplicity of infection of
2 PFU per cell. Procedures for infection of the suspension cultures and titration
of infectivity are described in Materials and Methods. Each value represents the
mean of duplicate assays.
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C-S8c1p100c10 and C-S8c1p100RGG populations (Fig. 4).
The presence of the RGD or RGG motif and of the mutations
associated with loss of heparin binding was confirmed by RT-
PCR amplification and nucleotide sequencing of the RNA of
progeny virus at 8 h postinfection. Likewise, none of the prog-
eny from infections with five C-S8c1p100RGG/hs2 clones re-
gained binding to heparin. As expected, the progeny of the
parental C-S8c1p100 RGG maintained its heparin binding.
Therefore, high FMDV yields can be produced in BHK-21
cells by FMDV that binds neither to integrin avb3 nor to HS.
Evidence for flexibility in FMDV receptor recognition. Syn-
thetic peptides representing the G-H loop of VP1 of FMDV
C-S8c1 are strong inhibitors of the infectivity of C-S8c1 for
BHK-21 cells, presumably by competing with virus for binding
to an integrin receptor (30, 48). Peptide A15, representing VP1
positions 136 to 150 of C-S8c1, did not inhibit the infectivity of
C-S8c1p100c10 or C-S8c1p100RGG (Fig. 5). Interestingly,
partial inhibition of infectivity by peptide A15 was observed
with clones from C-S8c1p100c10 deficient in heparin binding.
The clonal populations used were those harboring the single
amino acid replacement (Lys-173 3 Glu in VP3) associated
with loss of heparin binding, as determined by nucleotide se-
quencing of the capsid-coding region. The inhibition reached
90%, approaching the maximum inhibition of infectivity at-
tained with C-S8c1 in parallel assays (50% inhibitory concen-
tration of ’1 mM). In contrast, no inhibition by peptide A15
was observed with clones deficient in heparin binding derived
from C-S8c1p100RGG. None of the variants tested were in-
hibited by a variant version of peptide A15 which included
RGG instead of RGD in its sequence (Fig. 5). The ability to
regain sensitivity to inhibition by peptide A15 concurrently
with loss of heparin-binding capacity is not unique to FMDV
C-S8c1p100; it was also noted with a heparin binding-deficient
clone selected from FMDV MARLS, a MAR mutant isolated
FIG. 4. Replication in BHK-21 cells of FMDV clones unable to bind heparin. p100c10 and p100RGG denote FMDV C-S8c1p100c10 and C-S8c1p100RGG,
respectively; their origins are described in Materials and Methods. The five clones selected for the inability to bind heparin, termed hs-c1 through hs-c5, were selected
as detailed in the text (3). Infections of BHK-21 cell monolayers were carried out at a multiplicity of infection of 5 PFU per cell. Procedures for infection in liquid culture
and titration of infectivity are described in Materials and Methods. One representative experiment of three is shown for the parental p100c10 and p100RGG viruses.
FIG. 5. Inhibition of FMDV infectivity by peptides A15 and A15 with RGG instead of RGD. The amino acid sequences of peptides A15 and A15-RGG are given
in Materials and Methods. BHK-21 cell monolayers (about 5 3 105 cells) were treated with the indicated concentration of peptide A15 or A15-RGG for 45 min at room
temperature and further incubated in the presence of FMDV (50 to 150 PFU) for 45 min at 37°C. The monolayers were washed with 0.1 M phosphate buffer (pH 6.0)
and overlaid with agar containing medium as described in Materials and Methods. The FMDVs used in different experiments are listed in the right; hs- denotes a clone
selected for its inability to bind heparin. Origins of the viruses and procedures for selection of clones and infectivity assays are described in Materials and Methods.
Each value is the average of three determinations. Standard deviations are indicated.
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from population FMDV C-S8c1p213 described previously (3).
In the case of MARLS, however, the maximum inhibition by
peptide A15 was 58% (Fig. 5). These results suggest that
FMDV capsid structures selected upon propagation on
BHK-21 cells have retained the ability to interact with their
integrin receptor in an RGD-dependent manner and are able
to switch to integrin use when their HS binding pathway is
impeded. Internalization of FMDV RGG variants involves a
mechanism which does not implicate integrin avb3 or HS for
cell recognition and entry. Thus, FMDV can use multiple al-
ternative receptor molecules for infection of cells, and even for
one defined cell type it may shift to using one receptor class
when the use of another receptor is inhibited.
DISCUSSION
The RGD integrin-binding motif is highly conserved among
representatives of the aphthovirus genus, and isolates of each
FMDV serotype were found to bind purified integrin avb3 in
an RGD-dependent manner (38). Evidence of integrin mole-
cules being involved in the internalization of FMDV was ini-
tially provided by peptide inhibition experiments (4, 24) and
then by inhibition of infectivity by antibodies to avb3 (6), and
the use of cell lines modified to express avb3 (50). In spite of
virus-integrin interaction being essential for the infectivity of
FMDV isolated from cattle (50), FMDV harbors the evolu-
tionary potential to render dispensable the RGD motif upon
replication in cell culture (43). FMDV populations propagated
in BHK-21 cells may generate a different repertoire of anti-
genic variants, including some with substitutions at the RGD
motif (43, 58). In the present study, we have constructed in-
fectious FMDV clones to document that dispensability of the
RGD motif is conditioned to a number of amino acid replace-
ments in the FMDV capsid. The Asp-1433Gly change was
lethal in the context of the capsid proteins of C-S8c1, while the
same replacement yielded viable viruses in the context of the
capsid protein of C-S8c1p100 and C-S8c1p213. Therefore, it
was the amino acid replacements in the viral capsid (Fig. 1)
selected upon serial passages of FMDV C-S8c1 in BHK-21
cells that enabled the virus to find an alternative pathway for
entry into cells and to render the RGD nonessential for infec-
tivity. In the electroporation experiments, an average of 105
RNA molecules were introduced per BHK-21 cell, allowing
revertants to arise in all experiments. Since the progeny from
the electroporation was distinct from the input genome, the
FMDV RNAs encoding RGG behave as quasi-infectious ge-
nomes, as defined by Gmyl et al. (26; reviewed in reference 28).
The capsid of FMDV C-S8c1p100 or C-S8c1p213, but not
that of the parental C-S8c1, enabled virus replication in K-562
cells which do not express integrin avb3 (14). Thus, other cell
surface molecules such as HS (50) must act as receptors for the
FMDVs adapted to BHK-21 cells. RGD-mediated interactions
of FMDV capsid with a5b1 or other integrin molecules ex-
pressed at the surface of K-562 cells (14) could be partially
responsible for FMDV internalization in this particular cell
line and perhaps also for a limited viral production seen in
infections with O1K/C-S8c1 (Fig. 3). Yet the absence of de-
tectable differences between virus production on K-562 cells by
recombinant variants differing only at the RGD sequence sug-
gests that recognition of K-562 cells by FMDV occurs mainly
through RGD-independent mechanisms.
Binding to heparin is a phenotypic trait that characterizes
many cell culture-adapted FMDV variants, and virus interac-
tion with cell surface HS may constitute a major step toward
FMDV adaptation to cell culture (3, 37, 50, 57). However,
several lines of evidence obtained with FMDV of serotype C
support the existence of alternative pathways for FMDV ad-
aptation to cells in culture. We previously reported that vari-
ants that were highly adapted to BHK-21 cells, including
C-S8c1p100RGG, displayed enhanced affinity for heparin, but
unexpectedly, binding to cell surface HS was not required for
efficient replication in glycosaminoglycan-deficient CHO cells
(3). In the present study, we have shown that biological selec-
tion allowed a complete reversion of the heparin-binding phe-
notype of FMDV variants that lack the RGD motif. These
variants infected cells via a mechanism which is independent of
integrin avb3 or HS. These results imply the existence of at
least three different pathways for entry of FMDV into host
cells. It is noteworthy that while the multiply passaged FMDVs
used HS as a receptor, they maintained the potential to inter-
act and use integrin avb3 as a receptor (Fig. 5). The potential
for simultaneous use of at least three alternative receptors for
entry into the same cell types confers functional flexibility on
FMDV to modulate receptor usage in response to environ-
mental modifications (differential expression of the various
types of receptors on cells, blocking of receptor recognition by
antibody binding, presence of inhibitors of one of the alterna-
tive entry pathways, etc.). It must be emphasized that not only
can genetic changes in the virus prompt usage of one receptor
in preference over another receptor, but the same capsid may
be driven to use one or another entry pathway.
There is increasing evidence that picornaviruses, as well as
many other RNA viruses, may use a number of alternative
receptors for attachment and entry into cells (10, 23, 32, 36).
The results of expansion of receptor usage of FMDV C-S8c1
reported here pose a number of interesting questions. One
relates to neutralization by antibodies which bind to the RGD
motif (13, 43, 61, 63) of viruses which do not use integrin avb3
as their receptor. A number of possible mechanisms are now
under investigation.
The dispensability of the RGD as a receptor recognition
triplet may greatly expand the repertoire of antigenic variants
mapping within site A of FMDV. In addition to a number of
replacements previously identified among MAb-resistant mu-
tants of C-S8c1p100 (43), we have recently identified highly
unusual variants including one with a GGG triplet instead of
the RGD (56). This suggests that viruses which use the same
surface site for receptor recognition and antibody binding har-
bor the potential of coevolution of cell tropism and antigenicity
and may undergo expansions of the repertoire of antigenic
variants when the site ceases to be essential for entry into the
cell. Finally, several multiply passaged FMDVs display an ex-
panded host range, exemplified by the acquisition of infectivity
for CHO cells (3, 57) and human K-562 cells (50) (Fig. 3).
Given the potential relevance of this expansion for FMDV to
become a new emergent pathogen for animal species other
than artiodactyls, the cell tropism of a number of additional
FMDV variants is currently under investigation.
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